Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 5.56B | 5.93B | 4.84B | 2.98B | 1.48B | 1.56B |
Gross Profit | 2.53B | 2.69B | 2.39B | 1.35B | 558.99M | 705.26M |
EBITDA | 334.86M | 566.25M | -343.40M | -168.66M | 240.52M | 367.03M |
Net Income | -393.13M | -177.71M | -1.13B | -574.33M | 49.40M | 207.15M |
Balance Sheet | ||||||
Total Assets | 7.95B | 8.15B | 7.69B | 8.67B | 6.64B | 6.55B |
Cash, Cash Equivalents and Short-Term Investments | 2.90B | 1.73B | 2.74B | 3.80B | 3.66B | 5.55B |
Total Debt | 1.86B | 2.05B | 1.40B | 1.50B | 0.00 | 0.00 |
Total Liabilities | 2.75B | 2.95B | 2.55B | 2.59B | 194.63M | 143.50M |
Stockholders Equity | 4.70B | 4.64B | 4.79B | 5.87B | 6.44B | 6.40B |
Cash Flow | ||||||
Free Cash Flow | 0.00 | -200.24M | 20.80M | 387.11M | 186.17M | -18.82M |
Operating Cash Flow | 0.00 | 219.03M | 464.00M | 483.38M | 198.15M | 360.70M |
Investing Cash Flow | 0.00 | -479.27M | -1.22B | -144.47M | -2.09B | -384.52M |
Financing Cash Flow | 0.00 | 664.63M | -303.96M | -200.78M | 1.00K | 15.25M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | 14.29B | 23.90 | ― | 1.26% | 27.15% | 24.58% | |
69 Neutral | 13.22B | 17.10 | 34.20% | 0.59% | 12.09% | 141.99% | |
67 Neutral | 14.06B | 117.84 | ― | ― | 28.99% | -16.50% | |
54 Neutral | 60.72B | -55.38 | -27.47% | ― | 32.51% | 40.51% | |
53 Neutral | ¥16.67B | ― | ― | ― | 17.83% | 87.36% | |
41 Neutral | 15.48B | -33.74 | -29.17% | ― | 24.80% | 12.00% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
HEROZ, Inc. reported a positive financial performance for the three months ended July 31, 2025, with significant year-on-year growth in net sales and profits. The company achieved a 7.9% increase in net sales and a notable rise in operating and ordinary profits, reflecting its strong market positioning and effective operational strategies. Despite a slight loss attributable to the owners of the parent, the company’s financial outlook remains optimistic with a forecasted increase in net sales and profits for the full year ending April 30, 2026.
The most recent analyst rating on (JP:4382) stock is a Hold with a Yen1150.00 price target. To see the full list of analyst forecasts on HEROZ, Inc. stock, see the JP:4382 Stock Forecast page.
HEROZ, Inc. announced the issuance of new shares as compensation for restricted stock to align the interests of its directors, executive officers, and employees with those of shareholders. This move aims to motivate key personnel by sharing stock price fluctuation risks and enhancing corporate value, with minimal dilution of 0.22% of the total issued shares.
The most recent analyst rating on (JP:4382) stock is a Hold with a Yen1073.00 price target. To see the full list of analyst forecasts on HEROZ, Inc. stock, see the JP:4382 Stock Forecast page.
HEROZ, Inc. reported its consolidated financial results for the fiscal year ended April 30, 2025, showing a 22.5% increase in net sales compared to the previous year, despite a decline in operating and ordinary profits. The company anticipates further growth in the upcoming fiscal year, with projected increases in net sales and profits, indicating a positive outlook for stakeholders.